Integrated BioPharma Reports 10.6% Revenue Decline in Q2 Fiscal 2026

Integrated BioPharma, Inc. reported a decline in financial performance for the second quarter of fiscal year 2026, ending December 31, 2025. The company recorded net sales of $11.3 million, a decrease of 10.6% from $12.6 million in the same quarter of the previous year. For the six-month period, net sales totaled $24.0 million, down 8.6% from $26.2 million in the prior year. The decrease in revenue was attributed primarily to reduced sales volumes to customers outside of the company's two major clients, Life Extension and Herbalife, which accounted for approximately 92% of consolidated net sales in the latest quarter.

The company's gross profit for the quarter was $29, a significant drop from $1.2 million in the prior year, leading to an operating loss of $914, compared to an operating income of $202 in the same quarter of 2024. For the six months, the operating loss was approximately $751, a decrease from an operating income of $692 in the previous year. The decline in profitability was influenced by a higher cost of sales, which increased as a percentage of net sales, rising to 99.7% from 90.7% year-over-year.

In terms of operational metrics, Integrated BioPharma's customer base remains concentrated, with two major customers representing a significant portion of sales. The company reported that approximately 89% of its consolidated net sales for the six months ended December 31, 2025, were derived from these two customers. The loss of any of these key clients could have a substantial adverse effect on the company's financial condition. Additionally, the company has seen a slight negative impact on its margins due to inflation and tightened labor markets, which have affected its ability to increase prices in line with rising operational costs.

On the balance sheet, Integrated BioPharma reported total assets of $23.5 million as of December 31, 2025, down from $24.9 million at the end of the previous fiscal year. The company’s cash position improved to $5.3 million, up from $3.6 million, reflecting a net cash inflow from operating activities of $1.9 million for the six months ended December 31, 2025. The company continues to focus on improving operational efficiency and reducing expenses, with plans to maintain its cost structure in line with sales while expanding its customer base to mitigate reliance on its major clients.

Looking ahead, Integrated BioPharma's management remains cautious about the economic environment, which could impact consumer spending and demand for its products. The company is committed to enhancing its operational efficiency and exploring new business opportunities to stabilize and grow its revenue streams. However, the ongoing challenges posed by inflation and competitive pressures in the market may continue to affect its financial performance in the near term.